Cystic fibrosis gastrointestinal disease – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:34:17 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Cystic fibrosis gastrointestinal disease – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Acceptability of Pancreas Powder for Patients with Cystic Fibrosis and Pancreatic Exocrine Insufficiency https://clinicaltrials.eu/trial/study-on-the-acceptability-of-pancreas-powder-for-patients-with-cystic-fibrosis-and-pancreatic-exocrine-insufficiency/ Wed, 29 Apr 2026 14:56:56 +0000 https://clinicaltrials.eu/trial/study-on-the-acceptability-of-pancreas-powder-for-patients-with-cystic-fibrosis-and-pancreatic-exocrine-insufficiency/ This clinical trial is focused on studying a condition called cystic fibrosis, which affects the lungs and digestive system. People with cystic fibrosis often have a problem called pancreatic exocrine insufficiency, where the pancreas does not produce enough enzymes to help digest food. The trial is testing a new formulation of a medication called Creon, which contains a mix of enzymes, including pancreas powder. These enzymes help break down food so that the body can absorb nutrients better.

The purpose of the study is to evaluate how acceptable this new formulation of Creon is for patients. Participants will take the new Creon formulation, which comes in the form of gastro-resistant pellets, meaning they are designed to withstand stomach acid and dissolve in the intestines. The study will observe how patients feel about taking the medication, including aspects like taste, ease of swallowing, and overall convenience. The trial will also monitor any changes in symptoms such as stool frequency, consistency, and abdominal pain.

Participants will be involved in the study for a period of time, during which they will take the new Creon formulation and provide feedback on their experience. The study will also look at the safety and tolerability of the new formulation, checking for any side effects or issues with the mouth or digestive system. The trial aims to gather information on whether patients would prefer this new formulation over their current treatment.

]]>